Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Inclusion Criteria: * Histologically confirmed Stage IIIC unresectable cutaneous or mucosal melanoma with measureable disease or stage IV cutaneous, mucosal or ocular melanoma with measureable disease. * ECOG performance status of 0-2 * age greater than or equal to 18 years * ANC ≥ 1,500/µL * Platelet count ≥ 100,000/µL * Hemoglobin ≥ 10.0 g/dL * Creatinine ≤ 2 times upper limit of normal (ULN) * Total bilirubin ≤ 2 times ULN * LDH ≤ 5 times ULN * AST or ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastasis is present) * LVEF ≥ 50% on screening ECHO * women of childbearing potential must have a negative urine or serum pregnancy test upto 28 days prior to commencement of dosing. * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment * Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * before study entry , written informed consent must be obtained. Written informed consent must be obtained from patient prior to performing any study related procedures. Exclusion Criteria * pregnant or nursing * any following within the past 12 months: * Myocardial infarction * Severe and/or unstable angina * Coronary and/or peripheral artery bypass graft * Symptomatic congestive heart failure * Cerebrovascular accident or transient ischemic attack * Pulmonary embolism * ongoing cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0 * prolonged QTc interval on baselin…